BR0113374A - Derivados de bifenila e seu uso como inibidores da integrina - Google Patents

Derivados de bifenila e seu uso como inibidores da integrina

Info

Publication number
BR0113374A
BR0113374A BR0113374-8A BR0113374A BR0113374A BR 0113374 A BR0113374 A BR 0113374A BR 0113374 A BR0113374 A BR 0113374A BR 0113374 A BR0113374 A BR 0113374A
Authority
BR
Brazil
Prior art keywords
biphenyl derivatives
integrin
inhibitors
integrin inhibitors
arteriosclerosis
Prior art date
Application number
BR0113374-8A
Other languages
English (en)
Inventor
Wolfganf Staehle
Guenter Hoelzemann
Simon Goodman
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR0113374A publication Critical patent/BR0113374A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS DE BIFENILA E SEU USO COMO INIBIDORES DA INTEGRINA". A presente invenção refere-se a novos derivados de bifenila da fórmula geral (I), em que R^ 4^ representa um heterociclo aromático, e aos sais e solvatos fisiologicamente aceitáveis deste. Os compostos da invenção são inibidores da integrina e são usados para combater a tromboses, enfartes cardíacos, doenças cardíacas coronárias, arteriosclerose, inflamações, tumores, osteoporose, infecções e restenose seguinte a angioplastia ou para processos patológicos que são mantidos ou propagados pela angiogênese.
BR0113374-8A 2000-08-23 2001-08-02 Derivados de bifenila e seu uso como inibidores da integrina BR0113374A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10041423A DE10041423A1 (de) 2000-08-23 2000-08-23 Biphenylderivate
PCT/EP2001/008970 WO2002016328A1 (de) 2000-08-23 2001-08-02 Biphenylderivate und ihre verwendung als integrininhibitoren

Publications (1)

Publication Number Publication Date
BR0113374A true BR0113374A (pt) 2003-07-08

Family

ID=7653540

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113374-8A BR0113374A (pt) 2000-08-23 2001-08-02 Derivados de bifenila e seu uso como inibidores da integrina

Country Status (17)

Country Link
US (1) US20040010023A1 (pt)
EP (1) EP1311489A1 (pt)
JP (1) JP2004524264A (pt)
KR (1) KR20030022418A (pt)
CN (1) CN1447799A (pt)
AU (1) AU2001277561A1 (pt)
BR (1) BR0113374A (pt)
CA (1) CA2420208A1 (pt)
CZ (1) CZ2003671A3 (pt)
DE (1) DE10041423A1 (pt)
HU (1) HUP0301784A3 (pt)
MX (1) MXPA03001557A (pt)
NO (1) NO20030813L (pt)
PL (1) PL359668A1 (pt)
SK (1) SK2962003A3 (pt)
WO (1) WO2002016328A1 (pt)
ZA (1) ZA200302256B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10112771A1 (de) 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
DE10127041A1 (de) * 2001-06-02 2002-12-05 Merck Patent Gmbh Integrinantagonisten
DK1734996T3 (da) 2004-04-02 2013-06-10 Univ California Fremgangsmåder og sammensætninger til behandling og forebyggelse af sygdom, der er associeret med alfa v beta 5-integrin
WO2011011775A1 (en) 2009-07-24 2011-01-27 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with avb5 integrin
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
CA3054604A1 (en) 2017-02-28 2018-09-07 Morphic Therapeutic, Inc. Inhibitors of .alpha.v.beta.6 integrin
JP7365358B2 (ja) 2018-04-12 2023-10-19 モーフィック セラピューティック，インコーポレイテッド ヒトインテグリンα４β７のアンタゴニスト
WO2020047239A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
WO2021076890A1 (en) 2019-10-16 2021-04-22 Morphic Therapeutic, Inc. INHIBITING HUMAN INTEGRIN α4β7

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2242877A1 (en) * 1996-01-16 1997-07-24 Merck & Co., Inc. Integrin receptor antagonists
ES2221227T3 (es) * 1997-11-24 2004-12-16 MERCK & CO., INC. Derivados sustituidos de beta-alanina como inhibidores de la adhesion celular.
CN1146541C (zh) * 1999-02-20 2004-04-21 默克专利股份有限公司 β-丙氨酸衍生物

Also Published As

Publication number Publication date
HUP0301784A2 (hu) 2003-12-29
NO20030813D0 (no) 2003-02-21
PL359668A1 (en) 2004-08-23
NO20030813L (no) 2003-02-21
CN1447799A (zh) 2003-10-08
EP1311489A1 (de) 2003-05-21
HUP0301784A3 (en) 2004-03-29
SK2962003A3 (en) 2003-06-03
US20040010023A1 (en) 2004-01-15
CZ2003671A3 (cs) 2003-06-18
DE10041423A1 (de) 2002-03-07
JP2004524264A (ja) 2004-08-12
MXPA03001557A (es) 2003-06-06
AU2001277561A1 (en) 2002-03-04
KR20030022418A (ko) 2003-03-15
ZA200302256B (en) 2004-07-26
CA2420208A1 (en) 2003-02-21
WO2002016328A1 (de) 2002-02-28

Similar Documents

Publication Publication Date Title
BR0111263A (pt) Derivados de 2-aminocarbonil-9h-purina
DK0939627T3 (da) Pentaflourbenzensulfonamider og analoger
CY1105603T1 (el) Συνεργιστικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της ρενινης, για καρδιαγγειακες νοσους
TW200612195A (en) Oxime derivatives and the use therof as latent acids
CY1108041T1 (el) Αναστολεις της rho-κινασης
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
ES2062943B1 (es) Nuevos derivados de la (2-metil-3-piridil) cianometilpiperazinas.
ATE332903T1 (de) Kondensierte pyridoindolderivate
BR0111383A (pt) Benezenos 1,2,4-tri-substituìdos como inibidores de 15-lipoxigenase
AR027398A1 (es) Derivados de indol-3-ilo
TR200002542T2 (tr) Meta-azasiklik amino benzoik asit bileşikleri ve bunların integrin antagonistleri olan türevleri
ES2183332T3 (es) Aminoacidos biciclicos aromaticos.
BR0113374A (pt) Derivados de bifenila e seu uso como inibidores da integrina
NO20044526L (no) Hemisterlinderivater og anvendelser derav
AR025103A1 (es) Quelantes quimicos para la reversion del bloqueo neuromuscular inducido por farmacos
BR0109483A (pt) Pró-drogas de derivados de imidazopiridina
BR0008310A (pt) Derivados de alfa-alanina
BR0116202A (pt) Derivados de uréia e uretano como inibidores de integrinas
DE60112960D1 (de) Kondensierte pyridoindolderivate
BR0014990A (pt) Derivados de tetrahidrotiopirano ranftalazinona como inibidores de pde4
BR0012391A (pt) Derivados de diacilidrazina
ATE293111T1 (de) Kondensierte pyrazindionderivate als pde inhibitoren
UY27324A1 (es) Nuevas sales de napsilato i
BR0111813A (pt) Composições farmacêuticas e produto compreendendo derivados de distamicina acriloìla, e inibidores de topoisomerase i e ii, e seu uso
BRPI0408467A (pt) cromenonaindóis

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]